Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB)

2014 ◽  
Vol 33 (S3) ◽  
pp. S26-S31 ◽  
Author(s):  
Francisco Cruz ◽  
Victor Nitti
Keyword(s):  
Overactive Bladder ◽  
Clinical Data ◽  
Detrusor Overactivity ◽  
Neurogenic Detrusor Overactivity

scholarly journals Effectiveness and Safety of Intradetrusor OnabotulinumtoxinA Injection for Neurogenic Detrusor Overactivity and Overactive Bladder Patients in Taiwan—A Phase IV Prospective, Interventional, Multiple-Center Study (Restore Study)

Toxins ◽  
2021 ◽  
Vol 13 (12) ◽  
pp. 911
Author(s):  
Chung-Cheng Wang ◽  
Eric Chieh-Lung Chou ◽  
Yao-Chi Chuang ◽  
Chih-Chieh Lin ◽  
Yu-Chao Hsu ◽  
...  
Keyword(s):  
Overactive Bladder ◽  
Detrusor Overactivity ◽  
De Novo ◽  
Post Treatment ◽  
Neurogenic Detrusor Overactivity ◽  
Subjective Measures ◽  
Secondary Endpoints ◽  
Multi Center Study ◽  
Center Study ◽  
Phase Iv

We conducted a phase IV, pre/post multi-center study to evaluate the efficacy and safety of intradetrusor onabotulinumtoxinA injection in patients with neurogenic detrusor overactivity (NDO, n = 119) or overactive bladder (OAB, n = 215). Patients received either 200U (i.e., NDO) and 100U (i.e., OAB) of onabotulinumtoxinA injection into the bladder, respectively. The primary endpoint for all patients was the change in the PPBC questionnaire score at week 4 and week 12 post-treatment compared with baseline. The secondary endpoints were the changes in subjective measures (i.e., questionnaires: NBSS for patients with NDO and OABSS for those with OAB) at week 4 and week 12 post-treatment compared with baseline. Adverse events included symptomatic UTI, de novo AUR, gross hematuria and PVR > 350mL were recorded. The results showed that compared with baseline, PPBC (3.4 versus 2.4 and 2.1, p < 0.001) and NBSS (35.4 versus 20.4 and 18.1, p < 0.001) were significantly improved at 4 weeks and 12 weeks in NDO patients. In addition, compared with baseline, PPBC (3.5 versus 2.3 and 2.0, p < 0.001) and OABSS (9.1 versus 6.2 and 5.7, p < 0.001) were significantly improved at 4 weeks and 12 weeks in OAB patients. Eight (6.7%) had symptomatic UTI and 5 (4.2%) had de novo AUR in NDO patients. Twenty (9.3%) had symptomatic UTI but no de novo AUR in OAB patients. In conclusion, we found that intradetrusor onabotulinumtoxinA injections were safe and improved subjective measures related to NDO or OAB in our cohort.

scholarly journals Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity

2020 ◽  
Vol 8 (6) ◽  
Author(s):  
Stacey Tannenbaum ◽  
Martin den Adel ◽  
Walter Krauwinkel ◽  
John Meijer ◽  
Adriana Hollestein‐Havelaar ◽  
...  
Keyword(s):  
Overactive Bladder ◽  
Detrusor Overactivity ◽  
Neurogenic Detrusor Overactivity ◽  
Pediatric Populations
Sign in / Sign up

Export Citation Format

Share Document